Open-label, multicentre study to assess the persistence on treatment in women with postmenopausal osteoporosis receiving once-monthly ibandronic acid with either a patient support programme or bone turnover marker monitoring.
Phase of Trial: Phase III
Latest Information Update: 06 Apr 2011
At a glance
- Drugs Ibandronic acid (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Sponsors Roche
- 23 Feb 2010 New source identified and integrated (Roche, ML18373).
- 12 Jul 2006 New trial record.